[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oncological-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oncological-disease":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100634933","ovarian-tissue-cryopreservation-combined-with-oocyte-cryopreservation-versus-oocyte-cryopreservation-alone-100634933",false,"NCT07546123","Ovarian Tissue Cryopreservation Combined With Oocyte Cryopreservation Versus Oocyte Cryopreservation Alone","Ovarian Tissue Cryopreservation Combined With Oocyte Cryopreservation Versus Oocyte Cryopreservation Alone: an Observational Study in Oncology Patients","Inclusion Criteria:\n\n* Patient with oncological disease eligible for potentially gonadotoxic therapy\n* BMI ≥ 17.5 kg\u002Fm² and ≤ 32 kg\u002Fm²\n* Age ≥ 18 years and ≤ 46 years\n\nExclusion Criteria:\n\n* Hypersensitivity to one or more of the active substances used during ovarian stimulation treatment\n* Positive for HBV, HCV, HIV, or Treponema pallidum\n* Lack of oncological clearance","FEMALE","18 Years","46 Years",{"count":20,"type":21},127,"ESTIMATED","OBSERVATIONAL","Fertility preservation is a crucial aspect of care for oncological patients undergoing gonadotoxic treatments such as chemotherapy, radiotherapy, or surgery, which can significantly reduce ovarian reserve and cause infertility or premature menopause. Among available techniques, oocyte cryopreservation is well-established with high survival rates but requires controlled ovarian stimulation and may not be suitable for prepubertal patients or those needing urgent cancer therapy. Ovarian tissue cryopreservation offers advantages by preserving a larger number of primordial follicles, can be performed anytime in the menstrual cycle regardless of age, and also helps restore ovarian endocrine function.\n\nCombining ovarian tissue cryopreservation followed by oocyte cryopreservation may maximize fertility preservation by safeguarding more follicles and ensuring availability of mature oocytes.\n\nThis study will collect data from two patient groups:\n\nGroup 1: patients undergoing ovarian tissue cryopreservation followed by oocyte cryopreservation (combined treatment)\n\nGroup 2: patients undergoing oocyte cryopreservation alone.\n\nGroup assignment is based on planned gonadotoxic therapy and available time before treatment initiation, according to clinical practice.\n\nThe study aims to compare the number of oocytes retrieved per ovarian stimulation cycle between the two groups, along with the oocyte retrieval rate (number of oocytes retrieved\u002Fnumber of aspirated follicles), number of mature oocytes (metaphase II), incidence of moderate ovarian hyperstimulation syndrome within 7 days post-retrieval, and correlations between serum estradiol and luteinizing hormone levels on trigger day and oocyte yield.\n\nApproximately 127 patients aged 18 to 46 will be consecutively enrolled at the UO Gynecology and Human Reproduction Pathophysiology, IRCCS AOUBO Policlinico di Sant'Orsola. This is a cross-sectional, single-center, observational study with both retrospective and prospective enrollment. The retrospective period considered is from January 1, 2022, to the study start date. The study duration is 4 years and 3 months.",[25,26],"Oncological Disease","Fertility Preservation","RECRUITING","2026-04-20",{"date":30,"type":31},"2026-04-22","ACTUAL",{"date":33,"type":31},"2025-08-25",{"date":35,"type":21},"2029-09",{"name":37,"class":38},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":46,"targetDuration":48,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":51,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":39},"100634934","ovulation-induction-with-gnrh-analogue-or-dual-trigger-100634934","NCT07546136","Ovulation Induction With GnRH Analogue or Dual Trigger?","Inclusion Criteria:\n\n* Patient with oncological disease eligible for potentially gonadotoxic therapy\n* BMI ≥ 17.5 kg\u002Fm² and ≤ 32 kg\u002Fm²\n* Age ≥ 18 years and ≤ 46 years\n* AMH \\> 1.00 ng\u002FmL\n* Obtaining written informed consent to participate in the study and for data processing\n\nExclusion Criteria:\n\n* Hypersensitivity to one or more of the active substances used during the treatment",{"count":47,"type":21},200,"2 Weeks","Most medically assisted procreation (ART) techniques, including oocyte cryopreservation for fertility preservation, involve controlled ovarian stimulation. This procedure uses exogenous hormones, primarily follicle-stimulating hormone (FSH), to promote the development of multiple ovarian follicles in a single menstrual cycle. Once follicles reach a suitable number and size, oocyte retrieval (pick-up) is scheduled after pharmacological ovulation induction.\n\nHuman chorionic gonadotropin (hCG) has been routinely used for ovulation induction, but a common complication is ovarian hyperstimulation syndrome (OHSS). Studies have shown that in antagonist protocols, using a gonadotropin-releasing hormone agonist (GnRH-a) instead of hCG reduces OHSS risk. However, GnRH-a triggers luteal phase dysfunction, likely due to depletion of pituitary LH reserves and lack of LH-like activity (present in hCG), resulting in lower clinical pregnancy rates and occasionally very low oocyte yield.\n\nTo maximize oocyte retrieval and minimize OHSS risk, a combined \"dual trigger\" approach using both GnRH-a and hCG has been proposed, leveraging benefits of both agents.\n\nCurrently, limited data exist regarding the optimal ovulation induction strategy in oncological patients undergoing fertility preservation via oocyte cryopreservation before gonadotoxic therapy, where maximizing outcomes and minimizing complications is critical.\n\nThis study aims to compare the number of oocytes retrieved per cycle in oncological patients undergoing fertility preservation with ovulation induced by either GnRH-a alone or dual trigger (GnRH-a + hCG). It will also assess the oocyte retrieval rate (number of oocytes retrieved\u002Fnumber of follicles aspirated), number of mature oocytes, and incidence of moderate OHSS within 7 days post-retrieval in both groups. Additionally, it will explore correlations between serum estradiol (E2) and luteinizing hormone (LH) levels on the trigger day and oocyte yield.\n\nApproximately 200 patients aged ≥18 years will be consecutively enrolled over 2 years and 2 months. Retrospective period considered: from January 1, 2023, to the study initiation date. Patients will be assigned by clinicians to one of two groups based on clinical characteristics:\n\nGroup 1: Ovulation induced with 0.2 mg subcutaneous triptorelin (Decapeptyl®)\n\nGroup 2: Ovulation induced with 0.2 mg subcutaneous triptorelin plus 1000-5000 IU urinary hCG (Gonasi®)\n\nTreatment follows standard clinical practice.",[25,26],{"date":30,"type":31},{"date":53,"type":31},"2025-04-07",{"date":55,"type":21},"2027-04-03",{"name":37,"class":38}]